Key Takeaways
- Standalone guidance trimmed on Dahej delay, battery story intact: FY27 standalone revenue guided to ₹875–950 crore, down from the original ₹950–1,000 crore target, solely because labour shortages pushed Dahej commissioning into Q2. The battery chemicals business is still expected to deliver ₹300 crore+ in FY27, mostly in H2.
- Battery customer pipeline is filling fast: Three US electrolyte makers completed site audits, one domestic customer is scaling from 1 GW to 5 GW with Neogen as sole source, a second domestic customer approved the site in principle, and two giga-scale customers are testing Neogen’s electrolyte against Chinese supply.
- Project timelines are now concrete and funded: Dahej replacement plant commissions June 2026, Dahej Phase 1 by February 2027, Pakhajan Phase 2 by March 2027. Insurance proceeds of ₹140 crore received so far plus the $20 million Morita JV equity expected in H1 FY27 cover the remaining ₹800 crore capex without a debt peak increase.
- Margins held despite fire-related overheads: Q4 EBITDA margin stayed at 17.8% even with expansion overheads at Neogen Ionics, temporary toll manufacturing costs, and supply chain disruption from Middle East geopolitics. Operating leverage is expected as Pakhajan and Dahej scale.
- What to watch next quarter: Whether Dahej commercial supply actually starts by July–August 2026, the pace of customer audit closures for US electrolyte makers, and any movement in lithium or bromine prices that could alter the volume-driven revenue trajectory.
Battery Chemicals: Customer Pipeline & Qualification
- US electrolyte makers: Three have completed site audits at Pakhajan; post-audit corrections expected to close within one to two months, after which final commercial clearances should follow. Provisional approval from additional global customers for lithium electrolyte salts has already been received.
- Domestic giga-factory customer: Scaling from 1 GW to 5 GW within H1 FY27; Neogen is the sole source. Volume should be significantly higher than last year, though actual consumption depends on the customer’s own production and sales plan.
- Second domestic customer: Completed a site visit and audit, approved Neogen in principle; pilot line expected to start in Q2 FY27, with commercial production in 2027 at mega scale rather than giga scale.
- Two giga-scale customers testing: Both starting production later in calendar 2026; have submitted recipes and are currently testing Neogen electrolyte performance against Chinese supply. Once sufficient data is gathered, the qualification process will begin.
- Two more customers for 2027: Engaged in commercial and technical discussions with site visits completed; original intention is to switch from Chinese supply to Neogen.
- Pakhajan approval cycle expected to be shorter because testing methods, raw material supply, and manufacturing processes are already aligned with the existing Dahej site; only the site itself is changing.
Dr. Harin Kanani: "most of them were of the opinion that the approval cycle in Pakhajan will be shorter because our testing method, raw material supply, manufacturing, all of this is already aligned. Only just the site is changing."
Project Timelines, Capex & Funding
- Dahej replacement facility: Construction progressing rapidly, commissioning on track for June 2026; commercial supply expected by July or August 2026 without needing additional approvals since the site is already qualified.
- Dahej Phase 1: Budgeted at ₹428 crore, completion by February 2027. Of the 2,500 MT total, 1,500 MT was already completed by Q3 FY26; the balance 1,000 MT plus a new 500 MT intermediate facility will be completed by Q3 FY27, with some capacity possibly available in Q4.
- Pakhajan Phase 2: Revised cost of ₹1,367 crore, completion by March 2027 (SCOD approved by lenders). Electrolyte work targeted for H1 FY27, salt for H2; the facility should be mostly ready by end of Q3, with Q4 revenue possible but not yet factored into guidance.
- Funding secured without increasing peak debt: Insurance proceeds of ₹140 crore received cumulatively (₹60 crore in February 2026 alone), with the balance expected in a relatively short period. Morita’s $20 million equity contribution due in H1 FY27. Peak debt remains at ₹1,700 crore despite the capex increase.
- Moratorium terms: One year from revised start of commercial operations — for Pakhajan electrolyte from H1 FY27, for salt from H2 FY27, and for the Dahej sub-section from early Q3 FY27. Repayment schedule delayed to the same extent as the project startup delay.
- FY27 capex: Balance capex of around ₹600–700 crore plus approximately ₹100 crore in Neogen, totalling around ₹800 crore.
- FY28 capex: No fixed plans; the priority is to fully stabilize the plant and achieve full utilization. If both international and domestic demand materialize, salt and additive capacity may need to increase, but the extent is not yet decided.
Revenue Guidance & Segment Outlook
| Segment | FY27 Guidance | FY28 Outlook | FY29 Outlook |
|---|---|---|---|
| Standalone (base business) | ₹875–950 crore; original ₹950–1,000 crore still achievable if organolithium and lithium sales outperform | ~₹1,100 crore at full utilization with optimization | ₹1,200–1,250 crore |
| Battery chemicals (Neogen Ionics) | ₹300 crore+; majority in H2; sequential quarterly increases expected | ₹1,200–1,400 crore; more clarity in H2 FY27 | ₹2,500–2,900 crore |
| Consolidated | — | — | ₹3,700–4,200 crore |
- Standalone guidance reduction: The ₹75 crore trim from the original ₹950–1,000 crore target is entirely attributable to a slight delay in starting the Dahej plant caused by labour shortages. Full production from MPP-5 from Q2 FY26 onwards is assumed.
- Battery chemicals ramp: FY27 revenue of more than ₹300 crore is unchanged from prior guidance. The larger portion lands in H2 as giga factories come online and the Pakhajan site ramps up. FY28 could reach ₹1,200–1,400 crore, and at 80% salt capacity utilization alone, revenue crosses ₹1,000 crore.
- Longer-term capacity headroom: Brownfield expansions at Pakhajan can support ₹4,000–5,000 crore revenue by FY31; the site can go three times higher than the current 30 GWh capacity.
- Electrolyte pricing assumption: At $20 lithium with other raw materials, electrolyte prices are in the $6–8 per kg range, with $7–7.50 as the average.
Dr. Harin Kanani: "If we are able to outperform in that, then we would be able to even achieve the original INR 950 crore to INR 1,000 crore. But because there was a slight delay in starting the Dahej plant, that is why we said INR 875 crore to INR 950 crore."
Q4 Performance: Volume-Led Growth with Margin Resilience
- Revenue growth: 22% YoY and 12% QoQ, driven almost entirely by volume; only 2–3% came from value. Improved volumes and sustained high plant utilization across core businesses offset supply chain disruptions and elevated input costs from Middle East geopolitical developments.
- Organic Chemicals: Grew 7% YoY to ₹194 crore.
- Inorganic Chemicals: Delivered standout 145% YoY expansion to ₹53 crore, mostly volume-driven. Q4 is typically the strongest quarter for lithium; the business also added a few new customers and can now recycle lithium from the organolithium plant.
- EBITDA margin: Held at 17.8% despite expansion-related overheads at Neogen Ionics, temporary supply chain disruptions, one-off costs from the Dahej replacement facility, and an interim toll manufacturing arrangement.
- Employee cost: Declined ~22% sequentially, mainly due to a change in actuarial assumption resulting in a credit.
- Inventory build: Absolute increase driven by outside locations taken on rent for capacity (contracts ending March 2026), buildup to cover Q1/Q2 sales while Dahej is not fully online (extended by another month to month-and-a-half), and some product-mix-related requirements.
- Trade payables spike: Explained by longer credit terms negotiated with suppliers due to the fire-related situation; some suppliers obtained factoring against Neogen’s payment lines. Expected to come down as insurance money is received, with debtors and creditors stabilizing each other over the next 2–3 years.
Organolithium & Intermediate Salt Opportunities
- Organolithium performance: The current year has been strong, with one of the highest production levels achieved and peak monthly volume ever recorded in March. Approvals have been received in international markets for semiconductor applications, with a few more expected.
- Capacity utilization target: Aiming for 80–90% of the increased 300 MT capacity this year; a small capex to further increase capacity may follow if everything goes well.
- Intermediate salt facility: A 500 MT intermediate facility for simple lithium compounds has been added at Dahej, with the opportunity to sell to international customers including partners. Morita is positively considering purchasing this intermediate, and other established LiPF6 producers are also evaluating it to achieve a China-free requirement.
Dr. Harin Kanani: "Morita being our partner, they are positively considering to purchase this from us and other established LiPF6 producers are also considering to buy this intermediate from us to achieve the China-free requirement."
Commodity Prices & Competitive Position
- Lithium prices: One large jump occurred, followed by a slow increase, driven by higher ESS demand and some EV push from elevated gasoline and crude oil prices. Management considers $20 plus or minus as a long-term stable lithium price; abnormally low prices are gone. If the trend continues, prices may increase further, but this is difficult to predict.
- Bromine prices: Stabilized after Dead Sea Bromine arranged shipments to China following the war pause. If no further disruption occurs, prices may reduce from current elevated levels. Any sustained increase would impact topline but is not currently factored into budgeting.
- Commodity pass-through: Management does not factor commodity price increases into topline guidance because most are pass-through and do not materially impact EBITDA.
- Competitive moat: Neogen’s existing experience, the larger plant capacity needed to serve multiple customers, and the 30,000 MT plant built with Mitsubishi technology under trial production are cited as key differentiators. The price gap with China is around 20–25%.
- Single-supplier model: It is common for battery companies to work with only one electrolyte supplier; historically, companies have operated this way for decades, only adding a second supplier at very large volumes like 500 GWh. Neogen can meet 100% of its existing customer’s requirement.
Dr. Harin Kanani: "I normally do not factor in commodity price increase into how it will change our topline significantly because most of it is a pass-through and it is anyway something which is difficult to predict."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Dahej replacement plant commissioning | Commercial supply start | July–August 2026 |
| Dahej Phase 1 completion | Full 2,500 MT plus 500 MT intermediate capacity | Q3 FY27 (some capacity possibly Q4) |
| Pakhajan Phase 2 completion | Electrolyte H1, salt H2; mostly ready by end Q3 | March 2027 (SCOD approved) |
| FY27 standalone revenue | ₹875–950 crore (original ₹950–1,000 crore achievable if organolithium/lithium outperform) | FY27 |
| FY27 battery chemicals revenue | ₹300 crore+; majority in H2 | FY27 |
| FY28 battery chemicals revenue | ₹1,200–1,400 crore | FY28 |
| FY29 consolidated revenue | ₹3,700–4,200 crore | FY29 |
| ROCE on battery materials | 18–20% even after revised capex | At stabilization |
| Peak debt | ₹1,700 crore (unchanged despite capex increase) | Through project completion |
| Morita JV equity contribution | $20 million | H1 FY27 |
| Organolithium capacity utilization | 80–90% of increased 300 MT capacity | FY27 |
| Second domestic customer pilot line | Start pilot production | Q2 FY27 |
| Second domestic customer commercial production | Mega-scale volumes | 2027 |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Consolidated revenue | ₹247 cr, +22% YoY |
| Consolidated EBITDA | ₹44 cr, +21% YoY |
| Consolidated EBITDA margin | 17.8%, sustained despite expansion overheads and supply chain disruptions |
| Consolidated PAT | ₹11 cr |
| Organic Chemicals revenue | ₹194 cr, +7% YoY |
| Inorganic Chemicals revenue | ₹53 cr, +145% YoY |
| Neogen Ionics revenue | ₹13 cr (Q4), ₹36 cr (full year FY26) |
| FY27 standalone revenue guidance | ₹875 cr to ₹950 cr, non-battery business |
| FY27 battery chemicals revenue guidance | ₹300 cr plus, majority in H2 FY27 |
| Dahej Phase 1 project budget | ₹428 cr, completion by February 2027 |
| Pakhajan Phase 2 revised cost | ₹1,367 cr, expected completion by March 2027 |
| Consolidated total debt | ₹1,330 cr; net debt ₹1,295 cr |
| Cumulative on-account insurance claims received | ₹140 cr plus salvage realization of ₹7 cr; net claim receivable ₹203 cr |
| Promoter capital infusion | ₹161 cr through preferential allotment |
| Morita planned equity contribution | $20 million towards JV, expected H1 FY27 |